UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jul

    07

    UCB Awards Annual Myasthenia Gravis Scholarships to 15 Individuals Impacted by MG in the U.S.

    Read More

    Jun

    17

    UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)

    Read More

    Jun

    04

    Supporting Families During Dravet Syndrome Awareness Month: A look into Camp Small Steps

    Read More

    Jun

    03

    Running Toward Relief: How Cassie is Reclaiming Her Life With Psoriatic Arthritis

    Read More

    Jun

    01

    UCB Launches Career-Advancing Scholarship Program for Adults Living with Hidradenitis Suppurativa and Immediate Family Members

    Read More

    May

    19

    BIMZELX® (bimekizumab-bkzx) demonstrates superior efficacy over SKYRIZI® (risankizumab-rzaa) in psoriatic arthritis: BE BOLD Week 16 data

    Read More

    May

    14

    UCB Issues Voluntary Recall of Select Lots of CIMZIA® Pre-Filled Syringes (PFS) in the United States

    Read More

    May

    04

    UCB to acquire Candid Therapeutics, building upon its existing immunology pipeline with novel T-cell engagers

    Read More

    Apr

    17

    UCB to acquire Neurona Therapeutics, advancing its innovative leadership in epilepsy through regenerative science

    Read More

    Apr

    15

    UCB presents new data demonstrating quality-of-life impacts for epilepsy patients and caregivers at AAN 2026 meeting

    Read More